Vascular Biogenics Ltd (VBLT)

[gr8db8]

This is a must read Q&A with the CEO.

Lots of good info but this part summarizes upcoming key dates:

Q: What is your focus for the next 6-12 months?

- We expect to report full data from our Phase 2 trial of VB-111 in thyroid cancer, including Overall survival data by the end of 2016
- Plan to promote a potential-registration trial for VB-111 in ovarian cancer during 2017
- Expect interim data for the Phase 3 pivotal study in rGBM in 1H 2017
- Expect full data from the Phase 3 pivotal study at YE17/beginning of 2018.

Q: Can you tell us about your cash on hand, burn rate, upcoming rounds?

On June 30, 2016 we had $51.6M in cash, which takes us into 2019. This covers completion of the Phase 3 pivotal study in rGBM and the potential-registration trial for VB-111 in ovarian cancer.

Q: Can you tell us about the investment opportunity?

VBL is not actively seeking investments at this point, as we are well funded into 2019. That being said, we have many plans that we would like to implement, and we value smart-money and qualitative long-term investors.